ImmuCell Corporation — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $8M | ↓-1.6% | — | — | — |
| 2025-09-30 | $6M | ↓-8.4% | $-140K | ↑+80.1% | 0.4% |
| 2025-06-30 | $6M | ↑+17.8% | $502K | ↑+132.8% | 8.8% |
| 2025-03-31 | $8M | ↑+11.2% | $1M | ↑+430.5% | 13.9% |
| 2024-12-31 | $8M | ↑+52.1% | — | — | — |
| 2024-09-30 | $6M | ↑+11.4% | $-702K | ↑+25.4% | -9.6% |
| 2024-06-30 | $5M | ↑+54.9% | $-2M | ↓-11.0% | -25.3% |
| 2024-03-31 | $7M | ↑+110.6% | $-438K | ↑+81.1% | -4.1% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 63 quarters
margin trajectory tells the operating-leverage storyGo deeper
ICCC Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyICCC Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics